{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T15:03:17Z","timestamp":1725807797794},"reference-count":35,"publisher":"Hindawi Limited","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3309,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2006.00995.x","type":"journal-article","created":{"date-parts":[[2006,8,10]],"date-time":"2006-08-10T12:38:59Z","timestamp":1155213539000},"page":"1035-1039","source":"Crossref","is-referenced-by-count":8,"title":["Untoward effects of chronic dual renin-angiotensin system blockade: influence of previous chronic renal failure"],"prefix":"10.1155","volume":"60","author":[{"given":"N. R.","family":"ROBLES","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"CANCHO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"BARROSO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"MART\u00cdN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"S\u00c1NCHEZ CASADO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2006,8,10]]},"reference":[{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"11","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(95)91747-0","article-title":"Prevention of diabetic renal disease with special reference to microalbuminuria","volume":"346","author":"Mogensen","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0272-6386(00)70018-7","article-title":"Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials","volume":"35","author":"Kshirsagar","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk to terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"Gruppo Italiano Studi Epidemiologici in Nefrologia (GISEN)","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","article-title":"Pathophysiology of progressive nephropathies","volume":"339","author":"Remuzzi","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/ajkd.2001.25176","article-title":"Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy","volume":"38","author":"Russo","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004872-200018010-00013","article-title":"Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease","volume":"18","author":"Ruilope","year":"2000","journal-title":"J Hypertens"},{"issue":"Suppl. 82","key":"10.1111\/j.1742-1241.2006.00995.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1046\/j.1523-1755.62.s82.10.x","article-title":"Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies","volume":"62","author":"Lu\u00f1o","year":"2002","journal-title":"Kidney Int"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ndt\/17.6.1019","article-title":"Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy","volume":"17","author":"Jacobsen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semnephrol.2003.11.001","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues","volume":"24","author":"Mangrum","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1159\/000013394","article-title":"Effect of angiotensin-converting enzyme inhibitor of response to erythropoietin therapy in chronic dialysis patients","volume":"18","author":"Charytan","year":"1998","journal-title":"Am J Nephrol"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB21|cit21","first-page":"27","article-title":"Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients","volume":"26","author":"Hirakata","year":"1986","journal-title":"Clin Nephrol"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB22|cit22","first-page":"1428","article-title":"Does captopril decrease the effect of human recombinant erythropoietin in hemodialysis patients","volume":"8","author":"Walter","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB23|cit23","first-page":"45","article-title":"Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives","volume":"6","author":"Robles","year":"2003","journal-title":"J Clin Basic Cardiol"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/ki.1996.365","article-title":"Will angiotensin II receptors blockers be renoprotectives in humans","volume":"50","author":"Ichikawa","year":"1996","journal-title":"Kidney Int"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/ki.1992.311","article-title":"ACE inhibitors in renal disease","volume":"42","author":"Brunner","year":"1992","journal-title":"Kidney Int"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB28|cit28","first-page":"523","article-title":"Interrelation of the renin-angiotensin system and erythropoietin in rats","volume":"96","author":"Gould","year":"1980","journal-title":"J Lab Clin Med"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0272-6386(99)70431-2","article-title":"Erythropoietin deficiency in hyporeninemia","volume":"33","author":"Donnelly","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0041-1345(98)00562-4","article-title":"Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis","volume":"30","author":"Hortal","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007890-199408150-00010","article-title":"Efficacy of captopril on posttransplant erythrocytosis","volume":"58","author":"Torregrosa","year":"1994","journal-title":"Transplantation"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004872-200201000-00018","article-title":"Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade","volume":"20","author":"Ferrari","year":"2002","journal-title":"J Hypertens"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/ndt\/17.4.597","article-title":"Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal failure and proteinuria","volume":"17","author":"Kincaid-Smith","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00004872-200204000-00033","article-title":"Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition","volume":"20","author":"Berger","year":"2002","journal-title":"J Hypertens"},{"key":"10.1111\/j.1742-1241.2006.00995.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1755.2002.00536.x","article-title":"Dual renin-angiotensin system blockade at optimal doses for proteinuria","volume":"62","author":"Laverman","year":"2002","journal-title":"Kidney Int"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2006.00995.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2006.00995.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:38Z","timestamp":1643349878000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2006.00995.x"}},"subtitle":["DUAL RAS BLOCKADE SAFETY"],"short-title":[],"issued":{"date-parts":[[2006,8,10]]},"references-count":35,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2006.00995.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8,10]]}}}